• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A report from the 26th International Conference on Antiviral Research (May 11-15, San Francisco, California, USA)

tetano

Editor, Senior Moderator
Drugs Today (Barc). 2013 Jun;49(6):411-417.
A report from the 26th International Conference on Antiviral Research (May 11-15, San Francisco, California, USA).
Rabasseda X.
Source

Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com.
Abstract

As described in the following report, numerous research programs reported during this year's International Conference on Antiviral Research (ICAR) in San Francisco resulted in novel agents with antiviral activity against a number of viral pathogens, including programs aimed at compounds active against specific pathogens as well as broad preclinical research that identified compounds with putative activity against many virus families. As an example of the latter, a research program was reported that identified compounds with activity against HIV-1 and -2, herpes virus, influenza virus and Coxsackie virus (Dejmek, M. et al., Abst 35), while studies with Griffithsin, a red algae-derived protein with potent, broad antiviral activity against hepatitis C virus, coronavirus and Japanese encephalitis virus, among others, showed it also inhibited HIV, although only when the tight dimer structure is respected (Xue, J. et al., Abst 104).

Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.
KEYWORDS:

Anti-hepatitis agents, Anti-herpesvirus agents, Anti-influenza drugs, Antiretroviral drugs

PMID:
23807944
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23807944
 
Back
Top Bottom